We analyze two joint decisions in the management of HIV-infected patients on antiretroviral therapy: how frequently to measure a patient's virus level and when to switch therapy. The underlying stochastic model captures the initial suppression and eventual rebound of the virus level in the blood of a typical HIV-infected patient undergoing treatment.
INTRODUCTION
Combinations of reverse transcriptase and protease inhibitors have succeeded in suppressing the level of human immunodeficiency virus (HIV) RNA in the plasma of HIVinfected individuals to below the current level of detection (e.g., Hammer et al. 1997 ). The level of HIV RNA in the plasma -hereafter referred to as the viral load -has been established as the primary prognostic indicator of progression to AIDS (Mellors et al. 1996) . While the majority of HIV-infected patients experience sustained viral suppression on these potent drug regimens, initial indications from controlled clinical trials suggest that after one or two years the virus becomes detectable in the plasma in roughly 10-20% of patients prescribed a combination antiretroviral regimen (e.g., Hammer et al.) . The primary cause of this viral rebound is drug resistance: the high error rate of reverse transcription of viral RNA into DNA combined with the continual viral replication of HIV leads to the emergence of mutant strains of HIV that are drug resistant. Viral rebound can also be due to poor bioavailability of the drugs, nonadherence to the demanding drug regimen (up to 30 pills per day) and other factors.
Moreover, virus eradication by antiviral agents does not appear to be achievable in the foreseeable future , Wong et al. 1997 . In this environment, the goal of day-to-day clinical management is to delay the time until patients are resistant to all existing drug regimens. With this objective in mind, we consider how often a patient should be monitored and what changes in the viral load warrant a change in drug regimen. The crux of the tradeoff is between switching drugs too early, which risks poor adherence to a new drug reg-2 III imen and may prematurely exhaust the limited number of remaining salvage therapies, and switching drugs too late, which allows for the stepwise accumulation of mutations that leads to multidrug resistance (Molla et al. 1996 ). An expert panel convened by the International AIDS Society-USA (IAS-USA) recommends switching therapy when any increase in the viral load is observed (Carpenter et al. 1998 The two bodies of work that relate most closely to the problem studied here are the cancer screening (e.g., Eddy 1980 and references therein) and quality control chart design (e.g., Porteus and Angelus 1998 and references therein) literatures. Although all three problems focus on the tradeoff of false negatives and false positives, the HIV monitoring problem is sufficiently distinct from the other two problems to prevent direct adoption of existing methods. In particular, the underlying model for the viral dynamics is quite different and more complex than the tumor growth models and product attribute models used in cancer screening and quality control, respectively. Also, the cancer screening problem focuses on the frequency of screening, and has no analog to the decisions of when to switch HIV therapy or when to restore a production process. See D'Amato (1998) for a more detailed discussion of the relationship among these three problems.
In §2, we formulate the viral load model, and define the two performance measures and the two classes of policies under consideration. Section 3 contains approximate analytical expressions for the two performance measures under both classes of policies. A computational study in §4 assesses the accuracy of the approximations and compares the efficacy of the two policies. Concluding remarks are provided in §5. In D'Amato et al., the patient is administered combination therapy, and is assumed to be in a drug-sensitive stage for an exponential amount of time referred to as the time to rebound (see Figure 1) . During the drug-sensitive stage, the simulation model assumes that the viral load decays in a tri-phasic manner. The first phase of exponential viral decay is due to the loss of productively-infected CD4 + T cells (Ho et al., Wei et al.) . This compartment of cells is typically eliminated within several weeks. The second, slower phase 4 III of exponential viral decay is due to the depletion of an infected long-lived cell population, such as macrophages (Perelson et al. 1997) , and lasts for several years. The third and slowest phase of exponential viral decay is due to the loss of a latently-infected cell population (Chun et al. 1997) , and current estimates suggest that the duration of this phase is roughly a decade (Finzi et al., Wong et al.) . The existence of any even slower decaying, small compartments or any sanctuaries (e.g., the brain) that are unaffected by antiretroviral agents is currently unknown. The simulation model assumes that the third phase of decay lasts until the time to rebound. In the simulation model, the viral load achieves its minimum value, or nadir, at the time to rebound. After a random amount of time referred to as the time to exponential growth (typically lasting between several weeks and several months), the viral load increases exponentially until it reaches its pre-treatment value, after which it remains constant. The viral load is assumed to be quadratic and increasing during the time interval from when the nadir is achieved until the exponential rebound begins. Also, at a random amount of time (referred to as the time to opportunistic infection) after the viral nadir is achieved, the patient is assumed to develop an opportunistic infection. When this occurs, the patient visits a medical facility and drug failure is detected.
It is common medical practice to take a viral load measurement four weeks after the initiation of treatment to confirm that a patient is adhering and responding to treatment. given that a patient has not failed therapy during the first four weeks. This distributional assumption is based on a visual inspection of the data in Kempf et al. (1998) . Let ca be the exponential rate of decay in the macrophage stage and 3 be the exponential rate of viral rebound. Hence, if the time to rebound is denoted by r, then At, the log of the true viral load at time t, is given by
A key feature of this problem is that the viral load measurements are noisy and leftcensored. The measured log viral viral load at time t is assumed to be a normal random variable with mean At (i.e., the measurement is unbiased) and variance 2 
Policy Evaluation.
Each patient either switches from the current therapy before the viral nadir is achieved or switches therapy some time after the viral nadir occurs. Let the detection delay be the time interval from when the viral nadir occurs until therapy is changed. This quantity is defined only for those people who remain on the current therapy until a rebound occurs. The first of our two performance measures is the mean detection delay, where the expectation is only over those patients with a defined detection delay.
While the term "detection delay" is a misnomer when therapy is changed at time Ts under the proactive policy (because viral rebound is not actually detected in this case), we retain this terminology to maintain consistency with related literature. The second perfomance measure is the probability of pre-nadir switching, which is the probability that therapy is changed before the viral nadir is achieved.
III
It is desirable to have a small mean detection delay (false negatives) and a small probability of pre-nadir switching (false positives). Not surprisingly, there is an inherent tradeoff between these two quantities. As the monitoring policy becomes more aggressive (i.e., smaller values of At, A, and Ts), the mean detection delay decreases because when viral rebound does occur it is caught early, but the probability of pre-nadir switching increases.
This tradeoff leads us to consider the following constrained optimization problem: choose the screening interval At and the switching threshold A v (and the switching time Ts for the proactive policy) to minimize the mean detection delay subject to the restriction that the probability of pre-nadir switching is less than or equal to . Because we are interested in generating the entire efficient frontier for this tradeoff, we allow P to vary between 0 and 1.
To see how this optimization problem relates to our ultimate goal of delaying the time until the patient is not sensitive to any of the available drugs, let us suppose (although this is not included in our model) that all patients start on the same initial drug combination, and they all change to the same salvage drug combination at the time of the switch, perhaps
using the "what to switch to" guidelines in Carpenter et al. In §4.3, we argue that the risks of pre-nadir switching are independent of the exact time of the switch, and hence all patients who switch before the nadir is achieved have a similar prognosis (i.e., similar time until patients fail all available drugs) under the salvage therapy. In contrast, for patients who switch therapy after the nadir, the prognosis is worse for longer detection delays because of the accumulation of drug-resistant mutants. Hence, the solution to our optimization problem leads to the goal of delaying the onset of multidrug resistance.
It is worth noting that the proactive policy "buys more time" for the patient than the III viral load policy in the cases when therapy is switched before the nadir is reached, because the switch typically occurs during the first few visits under the viral load policy, and often occurs at a much later time, Ts, under the proactive policy. Consequently, by ignoring this issue in our optimization problem, we introduce a slight bias against the proactive policy.
Finally, our analysis does not include a cost comparison between the two classes of policies. Although D'Amato calculates the direct testing costs of these policies, a thorough analysis of the indirect costs warrants a separate study.
ANALYSIS
In this section, we analyze the two performance measures for both policies.
The Probability of Pre-nadir Switching. The Viral Load Policy. Let P(PS)
denote the probability of pre-nadir switching and let P(PS I -r) be the probability of prenadir switching given that the time to rebound equals r. Then
Let P(PS at iAt) be the probability of pre-nadir switching at time iAt (i.e., at the time of the ith measurement) given that the time to rebound is greater than or equal to iAt, and let Vi be the log viral load measurement at time iAt for i = 1,..., which are independent normal random variables with variance cr 2 and mean ui,t given by equation (1) .
For the viral load policy, we have
If we let cb denote the normal cdf then at the first screen,
(A -at \ Equation (4), which is at the heart of the analysis of the probability of pre-nadir switching, is difficult to calculate for i > 1 because it involves the minimum of several correlated normal random variables. To obtain an approximate expression for this quantity, we make three approximations. The first approximation is to assume that the viral load measurements are nonincreasing before the nadir is achieved; i.e., Vo > V 1 > ... > VL jA,.
so if At is sufficiently large (which turns out to be true for practically relevant values of At) then there is only a small probability that this assumption will be violated. Under this assumption, equation (4) becomes
The second approximation uses the following form of Slepian's inequality (Tong 1990) to obtain an upper bound to the right side of equation (6).
Slepian's Inequality: Let X and Y be normal K-dimensional vectors with mean vector A and covariance matrices e = (Ojk) and r = (jk), respectively. If Ojj = jj for all j and
To use this inequality, we rewrite the last term of equation (6) By our construction, Slepian's inequality yields
< P(X1 < A, ... ,Xi_ 1 < AV Xi < -AV) (10)
12 III If we treat Slepian's inequality as an approximation then equations (3), (5), (6) and (12) imply that i=2 some + (13) After some simplification, equations (2) and (13) give
j=l where Pi is defined in (5) and
The terms in equation (14) eventually tend toward zero. Our third and final approximation in calculating the probability of pre-nadir switching is to truncate the terms in (14) after the true log viral load drops below d -1.5u. The probability of pre-nadir switching when the log viral load drops below this value is small. The time for the load to drop below
to be the last screen before this time. Hence, we approximate the probability of pre-nadir switching by
j=1
We now report several structural properties of the approximation in (16) . D'Amato restricts attention to the first three terms in (16), which should not affect our qualitative conclusions. She finds that the first three terms are decreasing in the screening interval A t and the switching threshold A,. The first two terms are convex in A t and A, and the third term is convex for sufficiently large At and A v . Hence, the first three terms in (16) are convex in our two decision variables when they are sufficiently large. We have not investigated joint convexity.
Finally, we compute the derivative of the probability of pre-nadir switching with respect to the mean time to rebound, A-1 , which is the model parameter with the biggest impact on performance in the sensitivity analysis in D'Amato et al. By (16) ,
As expected, the first derivative with respect to the mean time to rebound is positive, because the longer the expected time to the viral nadir, the more opportunities for pre-nadir switching. However, according to the approximation in (17) , the probability of pre-nadir switching is neither concave nor convex in the mean time to rebound.
The Proactive Policy. For the proactive policy, L J P(PS I) = E P(PS at iAt) for < T, and P(PSI ) = 1 for > T.
i=l Let nT = min{n, [1} denote the number of screens under the proactive policy, incorporating our truncation to n screens in (16) . By an argument similar to the one above (see As At and A/ increase, j=T 1 pj decreases, and so as the likelihood of pre-nadir switching due to changes in the viral load decreases, the likelihood of pre-nadir switching due to the switching time increases. As Ts approaches infinity, (21) approaches the corresponding quantity in (16) for the viral load policy. As A t and A, approach infinity, the probability of pre-nadir switching approaches e-XT, which is decreasing and convex in the switching time,
j=1 j=1
which is positive. Hence, the probability of pre-nadir switching under the proactive policy is increasing in the mean time to rebound. Since the switching time in practice typically occurs after the viral load drops well below the level of detection, we expect that nT = n will often hold. In this case, a comparison of (17) and (22) shows that the sensitivity of the probability of pre-nadir switching with respect to the mean time to rebound is greater with the proactive policy than with the viral load policy.
Chapter 5 of D'Amato contains two other approximations for the probability of pre-nadir switching for both policies. The first approximation is similar to the present one, but as its starting point considers the event that there is no pre-nadir switching. The second approximation is similar to the present one, but uses Slepian's inequality to construct a lower bound to (8) by employing perfectly inversely correlated random variables, rather than constructing an uper bound to (8) using iid random variables. The third approximation uses a different conditioning argument along with Clark's algorithm (Clark 1961 ), which approximates the mean and variance of correlated normal random variables. Computational results in D'Amato reveal that the first two approximations are roughly comparable to the approximation presented here, and the approximation based on Clark's algorithm is somewhat less accurate. Therefore, we omit these three approximations from the paper.
Mean Detection Delay. Viral Load Policy.
The most direct approach to approximating the mean detection delay is to derive the pdf of the detection delay. This approach was taken by D'Amato, but the resulting expression is very unwieldy, partly because it requires knowledge of the probability of pre-nadir switching. Consequently, we make two 
The analysis of DD(r) is complicated by the left-censorship of the viral load assay, and we make our second approximation for ease of analysis. We assume that the time that the viral nadir is achieved happens to coincide with the time of a measurement. This 
where, for notational convenience, we use the convention that [01 = 1. In the second case, where the minimum viral load measurement is less than the detection limit, the viral rebound cannot be detected until the log viral load climbs from its nadir, ,u -r, to d + A,, and so
Let td = max{O, Ed} be the time at which the log viral load of a drug-sensitive patient oa becomes undetectable. Then equations (23) 
1-e-t2 J ' [(e-td-e -(t+t) )+j(a+j+l) (e-=(td+tl+t2) e-(td+tl+(j+l)t2)
Hence, by (26) and (28), our estimate for the mean detection delay is If td > 0 and we use the approximation e -At2 -1 -At 2 (At 2 is much less than unity in most practical situations), then
This expression is positive, so our analysis suggests that the mean detection delay increases with the mean time to rebound, but is neither concave nor convex in the mean time to rebound.
Proactive Policy. The mean detection delay for the proactive policy can be approximated by a similar, but slightly more involved, argument; details can be found in D'Amato. The expression in (32) displays the same qualitative dependence on the screening interval, switching criteria, and time to rebound as does the detection delay for the viral load policy.
The mean detecton delay in (32) is increasing in T,, but is neither concave nor convex.
Using (32), we can compute aE(DD) but we have not been able to establish analytically whether this derivative is larger or smaller than the corresponding quantity in (31). 
However, the ceiling function and mod functions appearing in E(DD) prevent us from per- forming an explicit Lagrangian analysis. Furthermore, ignoring these functions is too crude an approach. Because a brute force search for the optimal proactive policy is somewhat burdensome, we consider two simpler approaches in §4.
COMPUTATIONAL STUDY
The goals of the computational study are to assess the accuracy of our analytical approximations and to compare the performance of the two classes of policies.
Experimental Design.
A simulation model provides a benchmark for our approximations in §3. The parameter values for our study can be found in Table 1 . These values are derived from clinical data and are discussed in detail in D'Amato et al; here we only make several comments about Table 1 . In D'Amato et al., we consider two different patient types, drug-naive and drug-experienced. The present paper only considers the latter type, who have already undergone antiviral therapy. These patients tend to have a larger initial viral load and a shorter time to viral rebound than patients who have not been exposed to antiviral agents. The mean time to rebound is based on an uncontrolled clinical environment, which is the targeted setting for our analysis. Although the decay and rebound rates are assumed to be known constants in the analytical model, they are discrete probability distributions (derived from a regression analysis of clinical data) in the simulation model, in an attempt to make the model more realistic. To compute our analytical results, we took the mean of these distributions as our known values. Simulation results not shown here reveal that the difference between using constant and random c and 3 is negligible. Finally, the detection limit of 20 copies/mL corresponds to the bDNA assay, which is currently the most sensitive viral assay in widespread use.
In the simulation study, we discretized the switching threshold A v by tenths and the screening interval At and switching time Ts by weeks. For each policy and choice of decision variables, the number of simulated patients was chosen so that, for performance measure Y, we have ?-lower95%CIendpoint < 0.16 for all Y, and < 0.03 on average. This condition resulted in the simulation of between 20,000 and 40,000 patients for each policy discussed below. In addition, we chose a monitoring horizon of 15 years to guarantee that few patients (< 0.02%) remain on the original therapy at the end of a simulation run. Figures 2 and 3 plot the simulated and estimated probability of pre-nadir switching and mean detection delay as a function of Av and At, respectively, for the viral load policy. Figure 4 plots the simulated and estimated probability nearly identical values can be derived using (19)- (21). The upper curve in Figure 5 represents an attempt to derive a closed-form expression for the switching time that might be useful in practice. Current clinical guidelines (Carpenter et al.) suggest a viral load policy with A v = 0 and At -13 weeks. The upper curve in Figure 5 uses these values, equations (21) and (34) A P ( _j=l pj e -j Figure 5 shows that the proactive policy with it = 1 week and A, = 0.8 outperforms the optimal viral load policy, under the same risk of pre-nadir switching. When the probability of pre-nadir switching is restricted to 3%, the proactive policy can achieve a detection delay which is 2.2 weeks shorter (18.5% reduction over the viral load delay), when the probability is 10%, the proactive policy saves 3.8 weeks (34.9%), and when the probability is 20%, it saves 4.5 weeks (45.9%). In contrast, the closed-form proactive policy in (35) does not perform as well as the optimal viral load policy. However, relative to the current clinical guidelines, which corresponds to (A, = 0, /t = 13, T, = oo) and achieves a mean detection delay of 20.53 (0.16) weeks and zero probability of pre-nadir switching, the closed-form proactive policy can reduce the detection delay considerably; e.g., it can cut the delay in half when a 20% probability of pre-nadir switching is allowed. We are now in a position to interpret the tradeoff curves in Figure 5 with respect to changes in the mean time to rebound is larger (smaller, respectively) for the viral load policy than the proactive policy, thereby confirming our comparison of (17) and (22).
Results. Accuracy of Analysis.

CONCLUDING REMARKS
Although the success of recently developed antiretroviral therapy is promising, viral rebound -caused primarily by drug resistance, poor bioavailability, high toxicity and noncompliance -remains a concern. This study has focused on two specific aspects of therapy management: how frequently to monitor patients and when to change therapy. Given the small number of salvage therapies currently available, these decisions are likely to have a significant clinical impact.
In this paper, we derive analytical estimates for the mean detection delay and the prob- 
